Ming Ren

Ming Ren


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
YQYan Qi
Yan Qi
XYXiang Yin
Xiang Yin
SWShuyu Wang
Shuyu Wang
HJHongquan Jiang
Hongquan Jiang
XWXudong Wang
Xudong Wang
HFHonglin Feng
Honglin Feng
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease causing death of motor neurons. This study investigated the roles of energy metabolism in the pathogenesis of ALS in the SOD1(G93A) transgenic mouse model. Control and SOD1(G93A) mice were administered with shcontrol or shPGC-1α in combination with PBS or TZD for 8 weeks. Gene expression was analyzed by quantitative real-time PCR and western blot. ROS and fibrosis were assessed with a colorimetric kit and Sirius staining respectively. Inflammatory cytokines were measured using ELISA kits. The levels of tissue ROS and serum inflammatory cytokines were significantly higher in SOD1(G93A) mice compared to control mice, and knocking down PGC-1α drastically increased cytokine levels in both control and SOD1(G93A) mice. Muscle fibrosis was much severer in SOD1(G93A) mice, and worsened by silencing PGC-1α and attenuate d by TZD. The expression levels of PGC-1α, SOD1, UCP2, and cytochrome C were substantially reduced by shPGC-1α and increased by TZD in muscle of both control and SOD1(G93A) mice whereas the level of NF-B was significantly elevated in SOD1(G93A) mice, which was further increased by PGC-1α silencing. These data indicated that disruption of energy homeostasis would exacerbate the pathological changes caused by SOD1 mutations to promote the pathogenesis of ALS.

22 January 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RBRunhua Bai
Runhua Bai
LALi An
Li An
WDWei Du
Wei Du
ZWZhiwei Wang
Zhiwei Wang
XQXiaokun Qi
Xiaokun Qi
YYYingxin Yu
Yingxin Yu
Background: Autoimmune glial fibrillary acidic protein astrocytopathy (A-GFAP-A) is an autoimmune central nervous system(CNS) disease characterized by GFAP IgG as a biomarker. Several cases of individuals with A-GFAP-A initially misdiagnosed as infectious diseases of the central nervous system have been reported in research. We report three cases of A-GFAP-A misdiagnosed as viral meningitis or tuberculous meningitis (TBM). We summarize recent cases of A-GFAP-A misdiagnosed as central nervous system infections through a literature review.Materials and methods: Three cases of A-GFAP-A were initially misdiagnosed as tuberculous or viral meningitis. Their diagnoses of A-GFAP-A were confirmed with positive GFAP-IgG in cerebrospinal fluid (CSF). We searched the PubMed database with the key words of “GFAP astrocytopathy”, “GFAP autoimmunity”, “GFAP autoantibody”, “intracranial infection”, “meningitis”, “misdiagnose”, and within the literature from Jan 1, 2015 to Mar 15, 2024, 40 cases with A-GFAP-A with positive GFAP-IgG in CSF who were previously misdiagnosed with intracranial infection were reported. The causes of misdiagnoses were summarized and analyzed.Results: Case 1 was a 41-year-old female, presenting with headache, fever, diplopia, and altered consciousness level. Anti-tuberculosis treatment was ineffective. Finally, with positive GFAP IgG in CSF, she was diagnosed with A-GFAP-A. Case 2 was a 74-year-old male, presenting with fever, excessive sweating, fatigue, and memory loss. Anti-tuberculosis treatment was ineffective. With positive GFAP IgG in CSF, he was diagnosed with A-GFAP-A. Case 3 was a 54-year-old male, presenting with fever, personality changes, and memory decline. Antiviral treatment was ineffective. His diagnosis was revised to A-GFAP-A after testing positive for GFAP IgG in CSF. Our study summarized a total of 40 patients with A-GFAP-A who were initially misdiagnosed as intracranial infections. The most common clinical phenotypes among 40 patients were mimicked meningitis, meningoencephalitis, meningoencephalomyelitis, encephalitis and encephalomyelitis.Conclusion: A-GFAP-A is a specific autoimmune meningoencephalomyelitis associated with GFAP-IgG, with lesions involved the brain, meninges, and spinal cord. It commonly presents with symptoms such as fever, headache, altered consciousness, tremor, seizures, and autonomic dysfunction. Brain MRI often shows characteristic linear perivascular radial enhancement perpendicular to the ventricles or nonspecific leptomeningeal enhancement. Early detection of GFAP-IgG in serum and CSF is essential for differential diagnosis.

1 November 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
FQFeng Qiu
Feng Qiu
KWKunyu Wang
Kunyu Wang
TLTingting Li
Tingting Li
DSDandan Song
Dandan Song
ZWZhiwei Wang
Zhiwei Wang
XQXiaokun Qi
Xiaokun Qi
Background: The differential diagnosis of Parkinson’s disease (PD) with multiple-system atrophy (MSA) is difficult because of their similarity in symptoms and signs. The objective of this study was to investigate the value of external anal-sphincter electromyography (EAS-EMG) and urethral-sphincter electromyography (US-EMG) in differentiating MSA from PD. Methods: A total of 201 patients, — 101 MSA and 100 PD — were recruited in this study. Average duration and amplitude of motor unit potentials (MUPs), percentage of polyphasic MUPs, amplitude during strong contractions, and recruitment patterns during maximal voluntary contractions were recorded and analyzed to assess diagnostic efficiency of EAS-EMG and US-EMG for MSA. Results: Significant differences in average MUP duration and recruitment patterns during maximal voluntary contractions were found between patients with MSA and patients with PD using both EAS-EMG (P<0.001, P<0.001) and US-EMG (P<0.001, P<0.001). The percentage of polyphasic MUPs and amplitude during strong contractions showed significant differences in MSA and PD using only EAS-EMG (P<0.001, P=0.005). Cutoff points for average MUP duration in EAS-EMG and US-EMG for differential diagnosis of MSA with PD were 10.9 and 11.1 milliseconds, respectively. With average MUP duration of EAS-EMG and US-EMG being applied jointly, sensitivity and specificity in distinguishing MSA from PD were 83.2% and 71.8%, respectively. Conclusion: EAS-EMG and US-EMG were sensitive and specific methods for the diagnosis and differential diagnosis of MSA, and the combination of both would improve the diagnostic rate of MSA compared to only one method being used.

18 June 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
ZWZuowei Wang
Zuowei Wang
XLXujuan Li
Xujuan Li
NLNingning Li
Ningning Li
LHLeping Huang
Leping Huang
JLJiawen Liu
Jiawen Liu
MRMing Ren
Ming Ren
Purpose: A substantial proportion of patients with major depressive disorder (MDD) does not respond or cannot tolerate to currently available treatments. This study was to assess the safety and tolerability of Remote Limb Ischemic Preconditioning (RLIPC) as an adjunctive therapy in patients with MDD. Patients and Methods: Enrolled patients underwent RLIPC, five cycles of simultaneous bilateral arm ischemia, 5 min and followed by reperfusion of each cycle, and once daily for eight consecutive weeks. Depression and anxiety severity, and quality of life were assessed every 2 weeks. Descriptive analysis was used for safety and tolerability data. Results: Thirty-seven participants completed at least one RLIPC. Twenty-four of them (64.9%) completed the study. Twelve patients prematurely discontinued the study due to poor adherence, and one due to a mild side effect. The changes in HRSD-17, GAD-7 and QOL-6 total scores from baseline to the endpoint were significant from the end of second week treatment onwards. The responder and remission rates were 59.46% (22/37) and 54.05% (20/37) at the endpoint, respectively. Conclusion: RLIPC was safe and well tolerated, and may be effective in reducing depressive symptoms in patients with MDD. Large studies are warranted to test its efficacy and safety as monotherapy or adjunctive therapy in the treatment of MDD.

1 March 2025 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
WLWanyan Li
Wanyan Li
YQYankun Qin
Yankun Qin
JWJinglei Wang
Jinglei Wang
LLLin Li
Lin Li
JGJunfeng Gao
Junfeng Gao
XSXiangzhong Shao
Xiangzhong Shao
Post-stroke depression (PSD) constitutes a significant complication that influences both patient survival and functional recovery following a stroke. Despite its prevalence, PSD still lacks a long-term, safe and effective treatment measure. Remote ischemic conditioning (RIC) is a simple and noninvasive procedure that exert neuroprotective effects. This pilot study aims to investigate the efficacy, safety, and feasibility of RIC as a preventive measure against PSD. Acute ischemic stroke patients within 15 days post-event were considered eligible for study enrollment. Fifty participants were recruited and underwent daily RIC treatments for a 12-month period. Depressive symptoms were assessed utilizing the Patient Health Questionnaire-9 (PHQ-9) and the Hamilton Depression Rating Scale (HAMD) at baseline, as well as at 1, 3, 6, and 12-months post-intervention. The study found a gradual improvement in depressive symptoms among the 50 patients who completed the study over the 12-month treatment period, as evidenced by a consistent decline in pertinent scores. Moreover, merely two patients experienced mild adverse reactions. The study's outcomes indicate that RIC is safe, well-tolerated, and feasible as a preventive measure for PSD. Consequently, it is advisable to conduct a comprehensive randomized controlled trial to further evaluate the effectiveness and safety of RIC in preventing PSD.

21 October 2021 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
RLRuolin Li
Ruolin Li
MRMing Ren
Ming Ren
YYYingxin Yu
Yingxin Yu
Background: Alzheimer's disease (AD) is the most common degenerative disease characterized by cognitive impairment, memory decline, and language disorder for which there is no effective treatment. Neurogenesis has been indicated in AD and may play an important role in the pathogenesis of AD. Targeting this pathway is a new idea for the treatment of the disease. A recent study reveals that the cellular prion protein (PrP), a receptor for Aβ oligomers, regulates neurogenesis, and its elevated expression is related to cell differentiation. The aim of the present study was to investigate the neuroprotective effects of 6D11 (PrP monoclonal antibody) via neurogenesis promotion in APP/PS1 transgenic mice and Aβ‐induced cell model of AD.Methods: In the present study, 9‐month‐old male APP/PS1 mice were injected with 6D11. Then, the Morris water maze was used to examine the spatial learning and memory abilities of the mice in both groups, and immunostained was used to assess the level of Aβ, neurogenesis, and neural stem cells (NSCs) differentiation.Results: 6D11 attenuated cognitive deficits in APP/PS1 transgenic mice, which was accompanied by a decrease of the deposition of Aβ. In addition, 6D11 treatment promoted differentiation of the existing hippocampal cells to neurons.Conclusions: Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Aβ‐induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Aβ peptide signal.